Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Peritoneal Tumor Microenvironment of Cancers on Cancer Hallmarks
Perspectives of Translational Medicine
- 1st Edition - June 27, 2024
- Editors: Yong Sang Song, Danny N. Dhanasekaran, Benjamin K. Tsang, Johji Inazawa, Massoud Mirshahi, Marc Pocard, Ciro Isidoro
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 0 4 0 - 3
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 4 0 4 1 - 0
Peritoneal Tumor Microenvironment of Cancers on Cancer Hallmarks: Perspectives of Translational Medicine provides readers with cutting-edge knowledge on tumor microe… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePeritoneal Tumor Microenvironment of Cancers on Cancer Hallmarks: Perspectives of Translational Medicine provides readers with cutting-edge knowledge on tumor microenvironment. By exploring multiple aspects on tumor microenvironment, it gives an integrative insight on cancer diseases ranging from diagnosis to prediction of prognosis and individualized treatment. The book discusses topics such as clinical significance of tumor microenvironment, tumorigenesis and cancer progression, histopathological features of cancer in peritoneum, immune cells in tumor, exosomal cell-to-cell interactions, and therapeutic approaches to target tumor microenvironment. In addition, it discusses tumor evolution during chemotherapy and metastasis and future perspectives on identification and validation of biomarkers using liquid biopsy. This book is a valuable resource for cancer researchers, oncologists, medical doctors, and several members of biomedical field who want to understand the complex microenvironment of peritoneal tumors.
- Discusses how to apply tumor microenvironment knowledge to diagnosis, prediction of prognosis, and individualized treatment of cancer
- Provides readers with up-to-date knowledge on translational medicine, focusing on bench-to-bedside approach for cancer treatment and diagnosis
- Presents collaborative research works from the perspectives of medical doctors, cancer researchers, basic biological scientists, and bioinformaticians to provide integrative insights on tumor microenvironment
Cancer researchers, oncologists, medical scientists, clinicians, graduate students
- Cover image
- Title page
- Table of Contents
- Copyright
- List of Contributors
- Introduction
- Chapter 1. What is the tumor microenvironment?
- Abstract
- 1.1 Introduction
- 1.2 Formation of malignant ascites
- 1.3 Immune cells
- 1.4 Fibroblasts and mesenchymal stem cells
- 1.5 Extracellular matrix
- 1.6 Hypoxia and reactive oxygen species
- 1.7 Tumor microenvironment after cancer therapy
- 1.8 Summary
- References
- Chapter 2. Clinical significance of peritoneal cancers
- Abstract
- 2.1 Highlights
- 2.2 Introduction
- 2.3 Etiology and epidemiology
- 2.4 Diagnosis and prognosis
- 2.5 Therapy and therapy resistance
- 2.6 Summary and perspective
- Acknowledgment
- Conflict of interest
- References
- Chapter 3. Tumor microenvironment of peritoneal carcinomatosis: the concept of premetastatic niche altered before tumor implantation
- Abstract
- 3.1 Highlights
- 3.2 Introduction
- 3.3 Peritoneal complex
- 3.4 Peritoneal wall as a premetastatic environment
- 3.5 Scar zone on the peritoneal surface as a niche for cancer cell implantation (animal model study)
- 3.6 Conclusion and perspectives
- References
- Chapter 4. Cellular models for peritoneal cancer research
- Abstract
- 4.1 What is peritoneal cancer?
- 4.2 Origin of peritoneal carcinoma
- 4.3 Peritoneal tumor cell line models
- 4.4 Fingerprinting
- 4.5 Mycoplasma
- 4.6 Passaging primary cultures and cryopreservation
- 4.7 Removal of contaminating mesothelial cells and fibroblasts from cultures of isolated peritoneal cells
- 4.8 Use of established peritoneal tumor cell lines
- 4.9 3D culture of gastric cancer cell lines derived from ascites
- References
- Chapter 5. Metabolism of cancer cells altered in peritoneal tumor microenvironment
- Abstract
- 5.1 Highlights
- 5.2 Introduction
- 5.3 Cellular components of peritoneal tumor microenvironment
- 5.4 Metabolic crosstalk in the tumor microenvironment
- 5.5 Peritoneal tumor microenvironment and glucose metabolism
- 5.6 Peritoneal tumor microenvironment and lipid metabolism
- 5.7 Peritoneal tumor microenvironment and amino acid metabolism
- 5.8 Metabolic reprogramming and chemoresistance
- 5.9 Therapeutic perspectives
- 5.10 Conclusion
- References
- Chapter 6. Cell-to-cell interactions in peritoneal tumor microenvironment
- Abstract
- 6.1 Introduction
- 6.2 Blood and lymphatic vessels
- 6.3 The omentum
- 6.4 Key biological functions of omentum
- 6.5 Sequential events carcinomatosis expansion in peritoneal cavity
- 6.6 Peritoneal carcinomatosis and immune response
- 6.7 Cancer cell clusters in peritoneal liquid
- 6.8 Hospicells, as a stromal cell-derived from ascites cancer cell clusters
- 6.9 Origin and markers of hospicells
- 6.10 Hospicells in the regulation of angiogenesis
- 6.11 Conclusion and perspective
- References
- Chapter 7. Diagnostic, prognostic, and therapeutic biomarkers of ovarian cancer
- Abstract
- 7.1 Introduction
- 7.2 Ovarian tissue markers
- 7.3 Genetic tissue markers
- 7.4 Circulatory biomarkers
- 7.5 Molecular markers
- 7.6 Urinary biomarkers
- 7.7 Human epididymis protein 4
- 7.8 Matrix metalloproteinase
- 7.9 Polyamines
- 7.10 MicroRNAs
- 7.11 Eosinophil-derived neurotoxin and osteopontin
- 7.12 Extracellular vesicles as ovarian cancer biomarkers
- 7.13 The role of CT and MRI in the assessment of peritoneal carcinomatosis
- 7.14 Detection of peritoneal carcinomatosis
- 7.15 Prediction of success of cytoreduction
- 7.16 Treatment response assessment after neoadjuvant chemotherapy (NACT)
- 7.17 Positron emission tomography and radiogenomics for ovarian cancer detection and prognosis
- 7.18 Characterization
- 7.19 T staging
- 7.20 N & M staging
- 7.21 Detection of recurrence
- 7.22 Prediction of treatment response
- 7.23 Prediction of prognosis
- 7.24 The other tracers for PET imaging
- 7.25 Radiogenomics
- 7.26 Artificial intelligence in ovarian cancer detection and prognosis
- 7.27 Artificial intelligence application in medical imaging and ovarian cancer
- 7.28 Opportunities and challenges
- 7.29 Looking into the future
- 7.30 Summary and conclusions
- Acknowledgment
- References
- Chapter 8. Current and future perspectives of xenograft models of human ovarian cancer
- Abstract
- 8.1 Introduction
- 8.2 Intraperitoneal dissemination of human OC cell lines in murine models
- 8.3 Human OC xenograft in murine models
- 8.4 Patient-derived organoid models of OC
- 8.5 Experimental models of tumor neovascularization and progression using the chick embryo chorioallantoic membrane assay
- 8.6 Comparison in characteristics of experimental models for ovarian cancer studies
- 8.7 Conclusion
- Acknowledgments
- Funding
- Conflicts of interest
- References
- Chapter 9. Tumor microenvironment and chemoresistance
- Abstract
- 9.1 Introduction
- 9.2 Ovarian cancer chemoresistance and immunoresistance
- 9.3 Plasma gelsolin and ovarian cancer chemoresistance
- 9.4 Future research directions and conclusion
- Acknowledgment
- References
- Chapter 10. Tumor microenvironment and metastatic progression of cancer
- Abstract
- 10.1 TGF-β signaling in the tumor microenvironment
- 10.2 Role of TGF-β in the tumor microenvironment
- 10.3 The therapeutic implication of anti-TGF-β reagent
- 10.4 Concluding remarks
- References
- Chapter 11. Role of microbiome and microbial extracellular vesicles in tumor microenvironment
- Abstract
- 11.1 Introduction
- 11.2 Why are human microbiome and microbial EVs important?
- 11.3 Microbial EV biogenesis
- 11.4 Relationship between dietary habit and gut microbiome composition
- 11.5 Role of microbiome in the pathogenesis of tumor
- 11.6 Role of microbiome as cancer hallmarks
- 11.7 Microbial EVs as a smart drug
- 11.8 Conclusion
- References
- Chapter 12. Tumor evolution during chemotherapy
- Abstract
- 12.1 Cancer evolution at a glance
- 12.2 Models of cancer evolution
- 12.3 Intratumor heterogeneity
- 12.4 The evolution of tumor microenvironment during malignant transformation
- 12.5 The effects of chemotherapy in tumor evolution
- 12.6 Conclusion
- Conflict of interest
- References
- Chapter 13. Tumor evolution during metastasis
- Abstract
- 13.1 The development process of tumor metastasis
- 13.2 Somatic mutations as an intrinsic mechanism in tumor evolution
- 13.3 Epigenetic regulation in tumor evolution
- 13.4 Seeds and soil
- 13.5 Evolution of tumor epithelial cells, also referred to as “seeds”
- 13.6 The TME, also referred to as “soil”
- 13.7 Single-cell analysis for studying tumor metastasis
- 13.8 Future directions
- References
- Chapter 14. Future perspective: identification and validation of biomarkers using liquid biopsy
- Abstract
- 14.1 Highlights
- 14.2 Introduction
- 14.3 Tumor circulome and liquid biopsy
- 14.4 Cellular components of tumor circulome in liquid biopsy
- 14.5 Molecular components of tumor circulome in liquid biopsy
- 14.6 Clinical applications
- 14.7 Summary and future perspective
- Acknowledgments
- References
- Index
- No. of pages: 378
- Language: English
- Edition: 1
- Published: June 27, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780128240403
- eBook ISBN: 9780128240410
YS
Yong Sang Song
Yong Sang Song, MD, PhD is currently Professor at Seoul National University, College of Medicine. He received his MD and PhD at the Seoul National University (1983 and 1994 respectively). He was elected as the chairperson of Korean Society of Urogynecology in 2006. He was selected as the Director of Cancer Research Institute at Seoul National University in 2009, and as the President of Korean Society of Cancer Prevention in 2012. He served as the President of International Society of Precision Cancer Medicine (ISPCM) in 2018. His major research interests are molecular mechanisms of tumors, especially the role of tumor microenvironment in cancer cell metabolism, chemoresistance and precision medicine in gynecologic cancer. He is particularly interested in the impact of components of tumor microenvironment in ovarian cancer progression.
Affiliations and expertise
Professor, Seoul National University, College of Medicine, Seoul, South KoreaDD
Danny N. Dhanasekaran
Danny N. Dhanasekaran, PhD, is Samuel Roberts Noble Foundation Endowed Chair in Cancer Research. He is Deputy Director for Basic Sciences and Director, SCC-COBRE & Center for Basic Cancer Research, Stephenson Cancer Center, University of Oklahoma Health Science Center, USA. Danny N. Dhanasekaran, PhD, is Samuel Roberts Noble Foundation Endowed Chair in Cancer Research. He is Deputy Director for Basic Sciences and Director, SCC-COBRE & Center for Basic Cancer Research, Stephenson Cancer Center, University of Oklahoma Health Science Center, USA.
Affiliations and expertise
Samuel Roberts Noble Foundation Endowed Chair in Cancer Research, Deputy Director for Basic Sciences, Director, SCC-COBRE & Center for Basic Cancer Research, Stephenson Cancer Center, University of Oklahoma Health Science Center, USABT
Benjamin K. Tsang
Benjamin K Tsang, PhD, is director of Reproductive Biology Unit, professor of Obstetrics & Gynecology and Cellular & Molecular Medicine; Life Research Institute, Interdisciplinary School of Health Sciences, Professor Emeritus, University of Ottawa; Senior Scientist, Chronic Disease Program, Emeritus Senior Scientist, Ottawa Hospital Research Institute.
Affiliations and expertise
Director, Reproductive Biology Unit, Professor, Department of Obstetrics and Gynaecology and Cellular & Molecular Medicine and the Interdisciplinary School of Health Sciences, University of Ottawa, CanadaJI
Johji Inazawa
Johji Inazawa, MD, PhD, is director/ specially appointed Professor, Research Core Center, Tokyo Medical and Dental University (TMDU), Emeritus Professor, TMDU, Japan.
Affiliations and expertise
Director, Bioresource Research Center, and Professor, Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, JapanMM
Massoud Mirshahi
Massoud Mirshahi, MD, PhD, is Professor, Research INSERM unit, Paris 7 University Paris Diderot, France.
Affiliations and expertise
Professor, Research INSERM unit, Paris 7 University Paris Diderot, FranceMP
Marc Pocard
Marc Pocard, MD, PhD, is Director Research INSERM unit, and Professor, Abdominal and Oncologic Surgery, Paris 7 University Paris Diderot, France.
Affiliations and expertise
Professor, Abdominal and Oncologic Surgery, Paris 7 University Paris Diderot, FranceCI
Ciro Isidoro
Professor Ciro Isidoro, Clinical Biochemistry and Clinical Molecular Biology, and Professor of Medical Oncology in the Department of Health Sciences, University of Piemonte Orientale, Italy.
Affiliations and expertise
Professor, Clinical Biochemistry and Clinical Molecular Biology, and Professor, Medical Oncology, Department of Health Sciences, University of Piemonte Orientale, ItalyRead Peritoneal Tumor Microenvironment of Cancers on Cancer Hallmarks on ScienceDirect